In partnership with Elanco Animal Health, Tsang plans to apply genomics-enabled technologies to the development of lysozymes.
Elanco will, in turn, conduct pivotal animal studies and manage the registration and manufacturing processes required to bring the lysozyme-enriched feed to market.
Todd Armstrong is the director of research and development for Elanco’s Nutritional Health business unit. “Antibiotics are vital to livestock production for the control and prevention of disease,” he says.
“Elanco is committed to the responsible and judicious use of antibiotics, so we are focused on identifying alternative nutritional strategies to replace their use for growth promotion.”
For Concordia, such partnerships with industry are crucial in applying research to marketplace solutions that benefit Canadians and the rest of the world.
“Research contracts and development programs like the Genomic Applications Partnership Program are effectively helping university experts harness the power of disruptive technologies,” says Christophe Guy, Concordia’s vice-president of Research and Graduate Studies.
“Moreover, in partnering with Elanco — a leader in its field — genomics researchers like Adrian Tsang can apply their research expertise to a pressing real-life problem and offer concrete solutions. At Concordia, we are extremely proud of this work, which results in contributions that address global sustainability issues.”
This marks the second time that Tsang has been awarded funding through the GAPP, which supports translational research and development projects as identified by industry, government, not-for-profits and other “receptors” of genomics knowledge and technology.
In 2014, Tsang received $6 million to work with Elanco to develop new enzyme combinations for pork and poultry producers.
Find out more about Adrian Tsang. For more information on GAPP-funded projects, visit Genome Canada.